Market Overview - Major U.S. indexes closed lower, with the Dow Jones Industrial Average down 0.2% to 48,367.06, S&P 500 down 0.1% to 6,896.24, and Nasdaq down 0.2% to 23,419.08 [1] Nio Inc. (NYSE:NIO) - Nio's stock increased by 3.00% to close at $5.50, with an intraday high of $5.79 and a low of $5.50; the 52-week range is $3.02 to $8.02 [2] - The rise is attributed to confirmation from China's National Development and Reform Commission that vehicle trade-in subsidies will continue through 2026, indicating ongoing government support for auto replacement demand [2] Profusa Inc. (NASDAQ:PFSA) - Profusa's shares surged 78.33% to $0.12, with an intraday high of $0.17 and a low of $0.11; the 52-week range is $0.065 to $2.40 [3] - In after-hours trading, the stock fell 14.12% to $0.10 [3] - The company announced a restructuring of its senior secured convertible notes, raising the conversion floor price from $0.10 to $0.35 to reduce potential shareholder dilution and strengthen its balance sheet [4] - Mandatory cash and equity amortization payments scheduled to begin in early 2026 were eliminated, easing near-term cash flow pressure [4] - Management framed the changes as a de-risking move to limit equity issuance at distressed prices while improving financial flexibility; however, Profusa remains a high-risk micro-cap company facing Nasdaq non-compliance and ongoing operational challenges [5] Nike Inc. (NYSE:NKE) - Nike's stock slightly dipped by 0.03% to $61.19, with a high of $61.30 and a low of $60.64; the 52-week range is $52.28 to $82.44 [6] - The stock rose 1.5% to $62.13 in extended trading following Apple Inc.'s CEO Tim Cook's purchase of $3 million worth of Nike shares, increasing his total stake to 105,480 shares valued at $6.04 million [6] FTAI Aviation Ltd (NASDAQ:FTAI) - FTAI Aviation's stock jumped 14.30% to $197.54, with an intraday high of $199.88 and a low of $176.68; the 52-week high is $199.88 and the low is $75.10 [7] - The rise follows the announcement of FTAI Power, a new business converting aircraft engines into power turbines for AI-driven power shortages, expected to begin production in 2026 [7] Under Armour Inc. (NYSE:UAA) - Under Armour's stock rose 7.64% to $5.14, with a high of $5.20 and a low of $4.91; the 52-week range is $4.13 to $8.72 [8] - The company's Class C stock spiked 8.59% to $4.93 [8] - The increase followed a large insider purchase by Fairfax Financial Holdings, which acquired 15.68 million shares, significantly boosting its stake in both Class A and Class C shares [9] - Under Armour reported second-quarter adjusted EPS of 4 cents, beating expectations, with a gross margin of 47.3%, down year over year but ahead of consensus [9] - The company guided fiscal 2026 revenue down 4% to 5% and adjusted EPS to 3 to 5 cents, citing soft demand and tariff pressures; it expanded its fiscal 2025 restructuring plan, adding $95 million in charges related to separating the Curry Brand, while lifting its fiscal 2026 adjusted operating income outlook to $95–$110 million [10] - Fairfax's increased stake signals confidence in Under Armour's restructuring and turnaround strategy for long-term gains [11]

Core Viewpoint - Gold prices are expected to experience a period of correction or consolidation in the first quarter of 2026 due to high-interest rates and cautious Federal Reserve expectations acting as short-term headwinds [1] Group 1 - The high-interest-rate environment is identified as a significant factor impacting gold prices [1] - Expectations that the Federal Reserve will maintain a cautious stance contribute to the short-term challenges for gold [1]

Bank holiday today, 31 December: All banks, including public and private banks, in Manipur and Mizoram will remain closed on Wednesday, 31 December, according to the Reserve Bank of India's (RBI) bank holiday calendar.The RBI releases a bank holiday calendar every year, according to which banks close their branches on national holidays, festivals, and other designated days.Why is there a bank holiday today?While there is a bank holiday in Mizoram for New Year's Eve celebrations, banks in Manipur will be clo ...

分组1 - The Shiller P/E ratio is a normalized valuation metric that compares the real price of an index to the average real earnings over the past decade, adjusted for inflation [1] - This ratio is utilized to assess the valuation of stocks and can indicate whether they are overvalued or undervalued based on historical earnings [1] 分组2 - The author of the article has a background in mechanical engineering and finance, indicating a blend of technical and financial expertise [1] - The author employs evidence and factor-based investing strategies in their personal portfolio, suggesting a disciplined approach to investment [1] - The article does not provide specific investment recommendations or advice, focusing instead on the analysis of the Shiller P/E ratio [3]

Core Viewpoint - The Federal Reserve is considering further interest rate cuts if inflation continues to decline, although there is division among officials regarding recent economic data [2][9]. Group 1: Interest Rate Decisions - The Federal Reserve cut interest rates for the third consecutive time during its December meeting due to concerns about a weakening labor market, despite inflation remaining above the 2% target [5]. - The minutes indicate that most Federal Open Market Committee (FOMC) members would support further rate cuts if inflation decreases as expected [3][9]. - Some FOMC members suggested maintaining the target range for interest rates unchanged for a period after the recent cut, emphasizing the need to address emerging labor market weaknesses [8]. Group 2: Economic Indicators - The latest Consumer Price Index (CPI) report indicated that inflation was at 2.7% in November, down from a previous 3% annual increase [6]. - The jobs report following the FOMC meeting revealed that unemployment rose to 4.6%, the highest level since 2021, highlighting concerns about labor market conditions [8]. - Many FOMC members noted reduced risks of tariffs driving inflation higher, while expressing concerns about potential deterioration in the labor market if interest rates remain elevated [9].

Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant financial losses for investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Inspire securities between August 6, 2024, and August 4, 2025 [1]. - Allegations include that the company failed to disclose poor demand for its product and had surplus inventory, which affected the transition to the new treatment [1]. - The lawsuit claims that Inspire Medical did not complete essential tasks for a successful product launch, contrary to their public assurances [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers [2]. - The company admitted that software updates necessary for billing were not effective until July 1, leading many centers to continue using an earlier version of the product [2]. - Following the announcement, Inspire's stock price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 per share [2].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws or unlawful business practices [1] Group 1: Company Overview - Soleno Therapeutics, Inc. is under scrutiny following a report by Scorpion Capital that criticized its only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [2] - The company's stock price experienced significant declines following negative reports and disclosures about Vykat XR, with a drop of approximately 7.41% on August 15, 2025, and a further decline of about 26.59% on November 5, 2025 [2][3] Group 2: Financial Impact - Following the Scorpion Capital report, Soleno's share price fell from $77.36 to $71.64, a decrease of $5.73 per share [2] - On November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price from $63.85 to $46.87, a drop of $16.98 per share [3]

Core Viewpoint - Trex Company, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On November 4, 2025, Trex reported Q3 2025 net sales of $285 million, which was 5% below the mid-point of its guidance and a sequential decline of approximately 26% [3]. - The company experienced a 12% decline in net income per share for the nine months ending September 30, 2025, compared to the same period in the previous year [3]. - Trex revised its FY 2025 sales growth guidance down to roughly 0% compared to 2024, indicating a muted outlook for the fourth quarter [3]. Stock Market Reaction - Following the disappointing results, Trex's share price fell by $14.61, or about 31.07%, from $47.04 on November 4, 2025, to close at $32.43 on November 5, 2025 [3]. Company Strategy - Trex had previously assured investors that its revised inventory strategy would reduce volatility associated with channel stocking and de-stocking, and aimed for FY 2025 sales growth of 5% to 7% [2].

Core Viewpoint - Kirby McInerney LLP is investigating Car-Mart, Inc. for potential violations of federal securities laws and other unlawful business practices by the company and/or its senior management [1] Group 1: Investigation Details - The investigation is focused on Car-Mart, Inc. (NASDAQ: CRMT) and its senior management's possible legal violations [1] - On July 15, 2025, Car-Mart announced a delay in filing its annual report due to management identifying the need for further review [1]

Corporate Update - MedMira Inc. reported its financial results for the quarter ended October 31, 2025 [1] - The company received Health Canada approval for its Reveal® TP (Syphilis) rapid test in Q1 FY2026 [1]